Not sure I see anything negative here except a lack of understanding from the writer of this foolish article. Anyone who follows the companies, the drugs and the clinical trials can clearly see Roche plans to replace Herceptin with Kadcyla in every possible indication. They are spending, have spent and continue to spend hundreds on millions on clinical trials for Kadcyla.
very unusual open this morning, down nearly $1 on low volume and coming back now. Great for traders, annoying for people looking for LT growth. I don't see any news or tweets, maybe an obscure analyst report is out there some where, or just profit taking from the recent mini run. Still waaaaay below fair value based on sum of the parts, but lacking catalyst over the next few months.
did you mention Jan is prime time weight loss season. Skip the gym, order Belviq and take a walk, do some push ups and sit ups, buy a bike...move your #$%$
1349 was the AH volume last night according to NASDAQ web site??? Where did you see this large AH volume? Was there some off market trading that was not listed in Nasdaq?
he's an angry guy, with good reason (assuming he's a frustrated long-time shareholder), but provides no constructive ideas/solutions. He should really find another hobby, something more fun, productive, or just trade the stock.
Thanks. I took a quick look and hopefully we will learn more about the development plans during, or after the oral presentation. It appears all 3 molecules have some activity. The patient population is so difficult/advanced it's really hard to determine success in these patients. The BT results appear most interesting IMO, but the trial size was very small. The Sanofi naked antibody also looks interesting, but early stage. The Sanofi ADC appears to require more testing to identify the best patient population, so it may not be a large market product and is not ready to move into phase III.
The IMGN pipeline looks interesting, but it appears IMGN investors are going to have to wait longer for any major value drivers from the pipeline other than Kadcyla. Since investors are tired of waiting, the BOD should take action now to get IMGN up to full value, or $24. (IMO and best guess based on a sum of the parts estimate)
yes, I had kind of written off the BT drug mostly because I don't know much about the company, but that looks interesting. The Sanofi drug is an antibody, not an ADC. The Sanofi-IMGN ADC in phase II update is an abstract, so it seems like that drug may not be competitive, which is disappointing. Not sure if that one uses the same linker and DM1. I seem to recall IMGN saying this ADC uses a non-potent, dummy molecule? I wish IMGN would spell out in detail on the web site, the molecule, linker and killing agent used for each molecule.
thanks, I never did see the numbers. That's strong considering the 4-day week and near the holidays. Can't wait to see the Jan-Feb numbers.
A vary large volume of calls have traded today compared to the usual volume and the price of the calls is up much more than the stock. This is worth noting. Why would the Dec 17 calls be bid at .20 of the Dec $18 calls at .15. Maybe something is up???
Feel free to question, challenge, or suggest improvements. I feel these values are very conservative:
SAR-$250MM (assumtions $100MM for phase II, $50 for phase 1, $25 for undisclosed)
AMGN- $200 (75 + 75 + 25 + 25)
NVS- $75 (25 x 3 all undisclosed)
$1BB= Pipeline valuation estimate excluding Kadcyla
$1BB= Present value of Kadcyla revs
$250= value of all technology, linkers, DM1, new technology
$2.4BB is the total and again I think this is very conservative. That's double the current valuation.. All IMO
Excellent article in FierceBiotech today regarding the rise in the number of early stage deals and rise in the prices paid. If you add the sum of the parts for each IMGN owned molecule, partnership deals, Kadcyla, cash and the technology, IMGN would probably be worth double the current valuation. I will take a double now and walk away happy. Get it done BOD before Junius does any more damage!
another beat down, better send a distress signal to AF at TSC and beg for help!
IMGN just needs one of the more richly valued partner drugs to work. Their deals with AMGN, LLY, NVS would provide more incentive for IMGN to be acquired. Genentech just has to pay 3-5% of revs, which could be significant when sales get into the $BB's.
I see what you are seeing, but just 22 minutes remaining, that would be a violent move. Maybe this gets resolved tomorrow.
JL probably won't let me ask any questions on the CC either, but I don't care. I just want the stock price to go up. If JL can make the price go up, I will be his biggest fan...well that might be going too far, but I will get off his back and maybe even buy him, or Cindy some flowers.
Based on the posts. Mafia Short criminals love to beat down early-mid stage biotechs. They are the scammers, good to see them in pain!
1) they don't employ any analysts, just journalists that say whatever their hedge fund owners tell them to say 2) you can't hold a stock you never bought, they have never said anything but sell ARNA since $1, so 3) why would anyone listen to AF or any of the other TSC jokers that should be jailbirds.